TO · MBX.TO
Microbix Biosystems Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Mississauga, ON L4Z 1P3
- Website
- microbix.com
Price · as of 2025-09-30
$0.26
Market cap 33.36M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $30.94 | +12,033.33% |
| Intrinsic Value(DCF) | $0.13 | -49.02% |
| Graham-Dodd Method(GD) | $0.12 | -53.33% |
| Graham Formula(GF) | $0.28 | +10.98% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $0.16 | $27.92 | $0.00 | $0.00 | $0.00 |
| 2012 | $0.22 | $25.60 | $0.00 | $0.00 | $0.00 |
| 2013 | $0.15 | $37.91 | $0.03 | $0.09 | $0.00 |
| 2014 | $0.75 | $202.35 | $0.30 | $0.15 | $0.04 |
| 2015 | $0.28 | $37.55 | $0.08 | $0.21 | $0.10 |
| 2016 | $0.21 | $25.46 | $0.09 | $0.23 | $0.13 |
| 2017 | $0.31 | $34.22 | $0.07 | $0.00 | $0.00 |
| 2018 | $0.20 | $48.38 | $0.08 | $0.00 | $0.00 |
| 2019 | $0.23 | $31.32 | $0.08 | $0.11 | $0.01 |
| 2020 | $0.46 | $270.40 | $0.00 | $0.00 | $0.74 |
| 2021 | $0.68 | $115.51 | $2.41 | $0.23 | $1.16 |
| 2022 | $0.43 | $33.85 | $0.87 | $0.25 | $0.14 |
| 2023 | $0.35 | $30.83 | $0.03 | $0.18 | $0.00 |
| 2024 | $0.33 | $171.50 | $1.63 | $0.34 | $1.53 |
| 2025 | $0.24 | $30.94 | $0.04 | $0.12 | $0.28 |
AI valuation
Our deep-learning model estimates Microbix Biosystems Inc.'s (MBX.TO) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $30.94
- Current price
- $0.26
- AI upside
- +12,033.33%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$0.13
-49.02% upside
Graham-Dodd
$0.12
-53.33% upside
Graham Formula
$0.28
+10.98% upside
About Microbix Biosystems Inc.
Microbix Biosystems Inc., a life science company, develops and commercializes proprietary biological and technological solutions for human health and wellbeing in North America, Europe, and internationally. It manufactures a range of critical biological materials for the diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment and proficiency (QAPs) that support clinical lab proficiency testing, assay development and validation, or clinical lab workflows. The company also applies its biological expertise and infrastructure to develop other proprietary products, primarily viral transport medium (DxTM) to stabilize patient samples for lab-based testing and Kinlytic Urokinase, a biologic thrombolytic drug used to treat blood clots. It sells QAPs to lab accreditation organizations, diagnostics companies, and clinical labs through a network of regional distributors. Microbix Biosystems Inc. was founded in 1988 and is headquartered in Mississauga, Canada.
- CEO
- Cameron L. Groome
- Employees
- 100
- Beta
- 0.38
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($0.13 ÷ $0.26) − 1 = -49.02% (DCF, example).